The cell and gene therapies in rare disorders market is expected to grow at a significantly high rate during the forecast period (2025–2034) and main ...
We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at ...
Highlights,Sarepta Therapeutics continues to expand its RNA-targeted and gene therapy treatments for rare ...
William Blair analyst Sami Corwin maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report) today. The company’s shares ...
Arrowhead Pharmaceuticals stock could remain under pressure in the near-term, but improved financial outlook and pipeline ...
Entrada Therapeutics' innovative Endosomal Escape Vehicle platform, poised to revolutionize drug delivery. Click here to read ...
The consensus price target for CRISPR Therapeutics AG (NASDAQ:CRSP) has been adjusted from $72.75 to $65, reflecting changes in financial performance and industry developments. Despite a quarterly ...
The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...
Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...
The co-chief investment officers at Neuberger Berman see a new dynamic in the stock market as investors move on from inflation worries You have no doubt seen warnings that the U.S. stock market is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results